Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.94 USD | -0.76% | -1.40% | -4.08% |
04-25 | Transcript : Core Laboratories Inc., Q1 2024 Earnings Call, Apr 25, 2024 | |
04-24 | Earnings Flash (CLB) CORE LABORATORIES Reports Q1 Revenue $129.6M, vs. Street Est of $124.5M | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Business Support Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.08% | 794M | B+ | ||
0.00% | 6.8B | - | - | |
-12.39% | 2.88B | B+ | ||
-11.15% | 2.72B | - | ||
-31.21% | 1.74B | - | - | |
+5.00% | 1.25B | - | ||
-7.31% | 1.06B | - | ||
-6.67% | 870M | - | ||
-13.72% | 768M | - | ||
+0.62% | 757M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLB Stock
- Ratings Core Laboratories Inc.